Literature DB >> 23746060

Recent advances in the synthesis of tubulysins.

Xu Xiangming1, Gregory K Friestad, Yao Lei.   

Abstract

Tubulysins are a family of natural tetrapeptides in clinical development as a consequence of their potent anticancer activity, even for multi-drug resistant carcinoma. Tubulysins inhibit tubulin polymerization by binding to the peptide binding site located near the vinca alkaloid binding site of tubulin. The limited availability and pharmacological profile of the tubulysins attracted synthetic and medicinal chemists to initiate programs towards their total synthesis. This paper reviews efforts toward the total synthesis of tubulysins and selected structure-activity relationship studies of tubulysin analogs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746060     DOI: 10.2174/13895575113139990063

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  5 in total

1.  Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Authors:  Carolyn A Leverett; Sai Chetan K Sukuru; Beth C Vetelino; Sylvia Musto; Kevin Parris; Jayvardhan Pandit; Frank Loganzo; Alison H Varghese; Guoyun Bai; Bin Liu; Dingguo Liu; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-08-26       Impact factor: 4.345

2.  Diastereocontrol in Radical Addition to β-Benzyloxy Hydrazones: Revised Approach to Tubuvaline and Synthesis of O-Benzyltubulysin V Benzyl Ester.

Authors:  Manshu Li; Koushik Banerjee; Gregory K Friestad
Journal:  J Org Chem       Date:  2021-10-12       Impact factor: 4.354

3.  Stereoselective access to tubuphenylalanine and tubuvaline: improved Mn-mediated radical additions and assembly of a tubulysin tetrapeptide analog.

Authors:  Gregory K Friestad; Koushik Banerjee; Jean-Charles Marié; Umesh Mali; Lei Yao
Journal:  J Antibiot (Tokyo)       Date:  2016-02-17       Impact factor: 2.649

4.  Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.

Authors:  Joseph A Reddy; Ryan Dorton; Alicia Bloomfield; Melissa Nelson; Christina Dircksen; Marilynn Vetzel; Paul Kleindl; Hari Santhapuram; Iontcho R Vlahov; Christopher P Leamon
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

5.  Synthesis and antitumor activities of 3-substituted-analine derivatives: structure modifications of Tuv part of tubulysins.

Authors:  Mingsha Shao; Xinfa Bai; Xuan Ma; Ning Yan; Lei Yao
Journal:  Chem Cent J       Date:  2018-11-15       Impact factor: 4.215

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.